deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00384826

Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.

Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Conditions Adenocarcinoma, Bronchiolo-Alveolar
Interventions erlotinib paclitaxel + carboplatine
Updated 6 times since 2017 Last updated: Feb 12, 2015 Started: Sep 30, 2006 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Adenocarcinoma, Bronchiolo-Alveolar, this trial is completed. The trial is conducted by Intergroupe Francophone de Cancerologie Thoracique and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Intergroupe Francophone de Cancerologie Thoracique
Data source: Intergroupe Francophone de Cancerologie Thoracique

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations